Targeted Drug Delivery Using Nanoparticles Patent Landscape Analysis Report 2026 Edition

Targeted Drug Delivery Using Nanoparticles Market Size, Growth Trends, and Industry Outlook

Targeted nanoparticle delivery sits between oncology, genetic medicine and drug formulation. Carriers between 20 and 200 nanometres in size are engineered to carry small molecules, nucleic acids or proteins to selected tissues and cells. Demand comes from drug developers who need higher local drug exposure with lower systemic toxicity, and from gene medicine programmes that require a vehicle for fragile payloads. Hospital cancer centres, biotechnology firms and large pharmaceutical groups all invest in the area.

The market growth is driven by the shift of nanoparticle platforms from passive liposomal formulations to ligand-guided and nucleic acid carriers that expand the treatable disease set. GLOBOCAN estimates recorded about 20 million new cancer cases worldwide in 2022, which sustains demand for tumour-selective carriers. More than 50 nanoparticle-based products are now cleared by the FDA, giving developers a defined regulatory route.

A 2016 meta-analysis found that a median of only 0.7% of an injected nanoparticle dose reaches a solid tumour, so every gain in delivery efficiency cuts dose and side effects. This gap drives sponsors toward antibody, peptide and aptamer targeting, and it explains the steady flow of ligand-conjugation patents. In June 2025 AbbVie agreed to acquire Capstan Therapeutics for up to USD 2.1 billion for a T cell-targeted lipid nanoparticle platform, which shows that large groups pay for selective carriers. North America leads revenue through its nanomedicine sponsors and cancer centres, while Asia Pacific adds manufacturing capacity fastest.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Targeted Drug Delivery Using Nanoparticles Patent Filing Trends and Innovation Activity

Filing activity in targeted nanoparticle delivery has grown with each wave of clinical validation. The first wave followed liposomal and albumin-bound taxane products, and the second followed the approval of lipid nanoparticle RNA medicines. Universities file the largest share of early-stage families, and pharmaceutical groups follow with composition, formulation and manufacturing claims.

The dataset covers about 23,800 patent families, with filings peaking in 2021 and 2024 as messenger RNA and gene editing programmes expanded. Around 250 patents were granted in 2025, and roughly 8,260 patents sit with the primary jurisdiction. Chinese applicants account for the fastest rise in new families since 2020.

Demand for tumour-selective and organ-selective carriers in oncology and genetic disease translates directly into rising claims on ligands, ionisable lipids and release triggers.

Scope of the Targeted Drug Delivery Using Nanoparticles Patent Landscape Analysis Report

This report covers patents and published applications on nanoparticle carriers designed to direct a drug or nucleic acid payload to a chosen tissue, cell type or intracellular compartment. Coverage includes lipid-based, polymeric, inorganic, protein-based, membrane-coated and dendrimeric carriers, together with their targeting ligands, release triggers and manufacturing methods.

Patent families are counted by priority date from 2010 to 2025 and grouped by assignee, jurisdiction, nanocarrier type, targeting mechanism and therapeutic area. Applications covering untargeted nanoparticle excipients, cosmetic nanoemulsions and diagnostic-only contrast agents are excluded from the core set.

Assignees analysed include universities and research hospitals, large pharmaceutical groups, nanomedicine specialists, gene medicine developers and contract development and manufacturing organisations.

Global Targeted Drug Delivery Using Nanoparticles Patent Landscape Analysis

Targeted Drug Delivery Using Nanoparticles Patent Filing Trend Analysis

Annual filings for targeted nanoparticle delivery grew at an estimated 11% per year between 2020 and 2024. Growth came from lipid nanoparticle patents for messenger RNA, small interfering RNA and base editing, which followed the 2020 and 2021 vaccine launches. Applicants also added claims on organ-selective lipids that direct payloads to the lung, spleen and bone marrow.

Granted patents trail filings by three to five years, so 2025 grants reflect applications from the 2020-2022 peak. Oncology still carries the largest claim count, and neurological and cardiometabolic claims are rising fastest from a smaller base. Litigation over ionisable lipid composition between lipid nanoparticle licensors and messenger RNA developers has raised the value of claim drafting around lipid structure.

Leading Companies and Assignee Analysis in the Targeted Drug Delivery Using Nanoparticles Patent Landscape

Geographic Analysis of Targeted Drug Delivery Using Nanoparticles Patent Activity

The report assesses patent activity across major jurisdictions, including:

• United States
• Europe
• China
• Japan
• South Korea
• India
• International and WIPO filings

China leads filing volume with about 35% of families, driven by university and provincial research programmes in tumour-targeted carriers. The United States ranks second and holds the highest share of pharmaceutical and gene medicine filings. Europe follows, with filings concentrated in Germany, France and the United Kingdom through the European Patent Office.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Targeted Drug Delivery Using Nanoparticles Technology Segmentation and Innovation Areas

The report segments the patent portfolio by nanocarrier, targeting mechanism and therapeutic area, including:

• Ligand-conjugated surface engineering
• Ionisable lipid and extrahepatic targeting chemistry
• Stimuli-responsive and triggered release systems
• Biomimetic and cell membrane-coated carriers
• Blood-brain barrier and tumour-penetrating transport

Among these, lipid-based nanocarriers account for the largest share of patent families, supported by messenger RNA, small interfering RNA and gene editing programmes.

Competitive Landscape and Emerging Trends in the Targeted Drug Delivery Using Nanoparticles Market

Competition combines academic technology originators with pharmaceutical groups that acquire or license platforms. Universities file first and license by field, while companies add composition, process and indication claims. Start-ups founded around a single carrier chemistry often become acquisition targets once early clinical data appear.

Companies are focusing on:

• Antibody, peptide and aptamer ligands for receptor-mediated uptake
• Ionisable lipid libraries with organ-selective biodistribution
• pH, enzyme and redox-triggered drug release
• Albumin-bound and polymeric carriers for taxanes and kinase inhibitors
• Receptor-mediated transcytosis carriers for the brain
• Targeted lipid nanoparticles for in vivo T cell engineering
• Hafnium oxide and gold nanoparticles for radiotherapy enhancement

Emerging innovation themes include selective organ targeting beyond the liver, in vivo cell reprogramming with antibody-decorated lipid nanoparticles, macrophage and neutrophil hitchhiking carriers, machine learning screening of ionisable lipid libraries and radiotherapy-enhancing inorganic nanoparticles.

Strategic Insights from the Targeted Drug Delivery Using Nanoparticles Patent Landscape

The field combines mature taxane and liposomal formulations with fast-moving gene medicine carriers. Patent clusters on ligand chemistry and ionisable lipids carry the most commercial weight in licensing, while release-trigger and biomimetic clusters remain open to new entrants.

Technology segments, assignees and jurisdictions in this report are mapped to commercial activity, and the report provides actionable intelligence supporting:

• Intellectual property strategy
• R&D prioritisation
• Competitive benchmarking
• Technology scouting
• Licensing evaluation
• Partnership assessment
• Investment analysis
• Market entry planning
• Portfolio expansion strategy

Research Methodology for the Targeted Drug Delivery Using Nanoparticles Patent Landscape Analysis

Patent data was drawn from the European Patent Office worldwide database, the United States Patent and Trademark Office, the China National Intellectual Property Administration, the Japan Patent Office and the World Intellectual Property Organization PCT collection. Queries combine CPC classes A61K 9/51, A61K 47/69, A61K 9/127 and B82Y 5/00 with keywords for ligands, nanoparticles and targeted delivery.

Records were screened for relevance and consolidated into patent families by priority date. Assignee names were normalised across subsidiaries, universities and research hospitals, and legal status was verified against national registers.

Market-side context draws on regulatory filings from the FDA, the European Medicines Agency and the National Medical Products Administration, company disclosures, clinical trial registries and peer-reviewed literature.

Related Reports

Nanomedicine Market

Non-Viral Drug Delivery Market

Microneedles for Drug Delivery Patent Landscape Report